Bioventix PLC

LSE BVXP.L

Bioventix PLC Interest Coverage Ratio for the year ending June 30, 2024

Bioventix PLC Interest Coverage Ratio is NA for the year ending June 30, 2024. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Bioventix PLC Interest Coverage Ratio for the year ending June 30, 2022 was 30,299.23.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

LSE: BVXP.L

Bioventix PLC

CEO	Mr. Peter John Harrison MA
IPO Date	April 29, 2014
Location	United Kingdom
Headquarters	27–28 Eastcastle Street
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.

Key trends

Past 5 years